Halozyme Therapeutics Inc (HALO)
NASDAQ · Healthcare · Biotechnology
Halozyme Therapeutics Inc is a Healthcare company with a market capitalization of $12.00B and a trailing P/E ratio of 29.7.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 11, 2026 | $1.22 | $1.76 | -30.6% |
| Q4 2025 | February 17, 2026 | $-0.24 | $2.20 | -110.9% |
| Q3 2025 | November 3, 2025 | $1.72 | $1.63 | +5.5% |
| Q2 2025 | August 5, 2025 | $1.54 | $1.27 | +21.3% |
| Q1 2025 | May 6, 2025 | $1.11 | $0.95 | +16.8% |
| Q4 2024 | February 18, 2025 | $1.26 | $1.16 | +8.7% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 13,295,961 | 10.82% | 7.3 | +0.5% |
| June 30, 2026 | 13,226,223 | 10.76% | 6.3 | +2.1% |
| June 15, 2026 | 12,948,289 | 10.54% | 7.8 | -5.1% |
| May 29, 2026 | 13,644,245 | 11.10% | 8.1 | +1.9% |
| May 15, 2026 | 13,389,887 | 10.90% | 6.7 | -6.9% |
| April 30, 2026 | 14,381,741 | 12.22% | 10.2 | +0.9% |
| April 15, 2026 | 14,257,845 | 12.12% | 10.6 | +1.5% |
| March 31, 2026 | 14,046,350 | 11.94% | 9.4 | +2.5% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Halozyme Therapeutics Inc's market cap?
As of August 13, 2026, Halozyme Therapeutics Inc (HALO) has a market capitalization of $12.00B.
What is Halozyme Therapeutics Inc's P/E ratio?
Halozyme Therapeutics Inc trades at a trailing price-to-earnings (P/E) ratio of 29.7. Its forward P/E is 14.0.
Does Halozyme Therapeutics Inc pay a dividend?
Halozyme Therapeutics Inc does not currently pay a dividend.
What sector is HALO in?
Halozyme Therapeutics Inc is in the Healthcare sector, specifically the Biotechnology industry.
What is Halozyme Therapeutics Inc's short interest?
As of the July 15, 2026 FINRA settlement, 13,295,961 HALO shares were sold short, or 10.82% of shares outstanding. Days to cover: 7.3. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was Halozyme Therapeutics Inc's revenue?
In its latest reported fiscal year (ending December 31, 2025), Halozyme Therapeutics Inc reported revenue of $1.40B and net income of $316.89M.
Ask your own questions about HALO
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.